Investigational drugs in clinical trials for Hidradenitis Suppurativa

ABSTRACT

Introduction: Hidradenitis suppurativa is a chronic skin disease with a significant unmet need for treatment options. Randomized controlled trials are few and only a single drug (adalimumab) has Hidradenitis as a registered indication.

Areas covered: The clinicaltrials.gov and the EudraCT clinical trials register for reported trials on Hidradenitis Suppurativa was searched on the 22–06-2017. Trials for upcoming new drugs for HS are reported focusing on drugs in phase I and II trials.

Expert opinion: Currently, MABp1, Secukinumab, CJM112, Apremilast and IFX-1 are being investigated in Phase I and II trials and offer theoretical and promising new treatment options. A trial with the drug MEDI8968 has been terminated with disappointing results. Metformin, Botulinum Toxin B, Provodine, Benzoyl Peroxide and intralesional triamcinolone are being tested as well. Treatment of Hidradenitis remains a challenge and quality RTCs are needed. Studies indicates a range of potential targets for therapy such as interleukin-1 and interleukin-17, but ‘broad-spectrum’ immunosuppressants like phosphodiesterase-4 inhibitors are being examined as well. A range of outcomes, including Physician Global Assessment, Sartorius scores and hidradenitis suppurativa clinical response are used in these trials, making future meta-analysis of the data difficult.

KEYWORDS:

• Hidradenitis Suppurativa
• Acne Inversa
• CJM112
• MABp1
• Apremilast
• IFX- 1
• Secukinumab
• MEDI8968

Article highlights

• Hidradenitis suppurativa have an unmet need for treatment options

• Clinicaltrials.gov and EudraCT was searched for ongoing unreported trials for Hidradenitis Suppurativa

• Secukinumab are currently in a Phase I trial. MABp1, CJM112, Apremilast and IFX-1 are in Phase II trials.

• Metformin are currently in a Phase III trial. Botulinum Toxin B, Provodine, Benzoyl Peroxide and intralesional triamcinolone are being tested for HS, but phase is not reported for these trials.

• Comparison of trials show significant variation in outcome measurement. A uniform core outcome set is recommended.

This box summarizes key points contained in the article.

Declaration of interest

G. Jemec declares honoraria from; AbbVie, InflaRx, Leo Pharma, MSD, Novartis, and Pierre Fabre for participation on advisory boards, and grants from; Abbvie, Janssen-Cilag, Leo Pharma, Novartis, Regeneron and Sanofi for participation as an investigator, and received speaker honoraria from; AbbVie, Galderma, Leo Pharma, and MSD. He has furthermore received unrestricte The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.d research grants from AbbVie, Leo Pharma and Novartis.

Additional information

Funding

This paper was not funded.